EA022562B1 - ПИРАНО[3,2-d][1,3]ТИАЗОЛ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОЗИДАЗЫ - Google Patents
ПИРАНО[3,2-d][1,3]ТИАЗОЛ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОЗИДАЗЫ Download PDFInfo
- Publication number
- EA022562B1 EA022562B1 EA201490493A EA201490493A EA022562B1 EA 022562 B1 EA022562 B1 EA 022562B1 EA 201490493 A EA201490493 A EA 201490493A EA 201490493 A EA201490493 A EA 201490493A EA 022562 B1 EA022562 B1 EA 022562B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- chiral
- compound
- atoms
- compounds
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527323P | 2011-08-25 | 2011-08-25 | |
| PCT/US2012/051785 WO2013028715A1 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201490493A1 EA201490493A1 (ru) | 2014-06-30 |
| EA022562B1 true EA022562B1 (ru) | 2016-01-29 |
Family
ID=46759099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490493A EA022562B1 (ru) | 2011-08-25 | 2012-08-22 | ПИРАНО[3,2-d][1,3]ТИАЗОЛ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОЗИДАЗЫ |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8884023B2 (enExample) |
| EP (1) | EP2748171B1 (enExample) |
| JP (1) | JP5893738B2 (enExample) |
| KR (1) | KR102008032B1 (enExample) |
| CN (1) | CN103930428B (enExample) |
| AU (1) | AU2012298949B2 (enExample) |
| BR (1) | BR112014004219B1 (enExample) |
| CA (1) | CA2845149C (enExample) |
| DK (1) | DK2748171T3 (enExample) |
| EA (1) | EA022562B1 (enExample) |
| ES (1) | ES2568603T3 (enExample) |
| HR (1) | HRP20160334T1 (enExample) |
| HU (1) | HUE029390T2 (enExample) |
| IL (1) | IL231008A (enExample) |
| MX (1) | MX358463B (enExample) |
| PL (1) | PL2748171T3 (enExample) |
| RS (1) | RS54773B1 (enExample) |
| SG (1) | SG2014009617A (enExample) |
| SI (1) | SI2748171T1 (enExample) |
| WO (1) | WO2013028715A1 (enExample) |
| ZA (1) | ZA201400387B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| BR112013016179A2 (pt) | 2010-12-23 | 2018-07-10 | Alectos Therapeutics Inc | inibidores seletivos da glicosidase e usos dos mesmos. |
| WO2012126091A1 (en) | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9718854B2 (en) * | 2011-03-31 | 2017-08-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000085A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| MX364602B (es) | 2011-06-27 | 2019-05-02 | Alectos Therapeutics Inc | Inhibidores selectivos de glicosidasa y usos de los mismos. |
| WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US8884023B2 (en) * | 2011-08-25 | 2014-11-11 | Merck Patent Gmbh | Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2914604A4 (en) | 2012-10-31 | 2016-07-20 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| WO2014100934A1 (en) * | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| MX381417B (es) | 2014-08-28 | 2025-03-12 | Asceneuron Sa | Inhibidores de glucosidasa. |
| US10571963B2 (en) * | 2015-09-18 | 2020-02-25 | Toray Industries, Inc. | Housing |
| JP6971999B2 (ja) | 2016-02-25 | 2021-11-24 | エースニューロン・ソシエテ・アノニム | ピペラジン誘導体の酸付加塩 |
| CN108884077A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| JP2019506430A (ja) | 2016-02-25 | 2019-03-07 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| CA3110032A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S.A. | Succinate and fumarate acid addition salts of piperazine derivatives |
| TW202130643A (zh) * | 2019-10-29 | 2021-08-16 | 美商百健Ma公司 | 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008025170A1 (en) * | 2006-08-31 | 2008-03-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006220187B2 (en) * | 2005-03-01 | 2012-11-08 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| AU2007210002A1 (en) * | 2006-01-30 | 2007-08-09 | Irm Llc | Compounds and compositions as PPAR modulators |
| CN101595111A (zh) * | 2006-08-31 | 2009-12-02 | 西蒙·弗雷瑟大学 | 选择性糖苷酶抑制剂及其用途 |
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013016179A2 (pt) | 2010-12-23 | 2018-07-10 | Alectos Therapeutics Inc | inibidores seletivos da glicosidase e usos dos mesmos. |
| US8884023B2 (en) * | 2011-08-25 | 2014-11-11 | Merck Patent Gmbh | Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors |
-
2012
- 2012-08-22 US US14/131,471 patent/US8884023B2/en active Active
- 2012-08-22 AU AU2012298949A patent/AU2012298949B2/en active Active
- 2012-08-22 EP EP12753341.2A patent/EP2748171B1/en active Active
- 2012-08-22 CA CA2845149A patent/CA2845149C/en active Active
- 2012-08-22 SG SG2014009617A patent/SG2014009617A/en unknown
- 2012-08-22 HU HUE12753341A patent/HUE029390T2/en unknown
- 2012-08-22 ES ES12753341.2T patent/ES2568603T3/es active Active
- 2012-08-22 HR HRP20160334TT patent/HRP20160334T1/hr unknown
- 2012-08-22 MX MX2014002031A patent/MX358463B/es active IP Right Grant
- 2012-08-22 CN CN201280041109.9A patent/CN103930428B/zh active Active
- 2012-08-22 SI SI201230534A patent/SI2748171T1/sl unknown
- 2012-08-22 PL PL12753341T patent/PL2748171T3/pl unknown
- 2012-08-22 DK DK12753341.2T patent/DK2748171T3/en active
- 2012-08-22 KR KR1020147002525A patent/KR102008032B1/ko active Active
- 2012-08-22 BR BR112014004219-5A patent/BR112014004219B1/pt active IP Right Grant
- 2012-08-22 RS RS20160280A patent/RS54773B1/sr unknown
- 2012-08-22 EA EA201490493A patent/EA022562B1/ru not_active IP Right Cessation
- 2012-08-22 JP JP2014527246A patent/JP5893738B2/ja active Active
- 2012-08-22 WO PCT/US2012/051785 patent/WO2013028715A1/en not_active Ceased
-
2014
- 2014-01-17 ZA ZA2014/00387A patent/ZA201400387B/en unknown
- 2014-02-17 IL IL231008A patent/IL231008A/en active IP Right Grant
- 2014-09-30 US US14/502,213 patent/US9469657B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008025170A1 (en) * | 2006-08-31 | 2008-03-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| KANPP ET AL.: "An allosamizoline/Glucosamine Hybrid NAGase inhibitor", SYNLETT, no. 5 Suppl. 1, 1 May 1997 (1997-05-01), pages 435-436, XP008104081, GEORG THIEME VERLAG, DE, ISSN: 0936-5214, compounds 7, 11 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102008032B1 (ko) | 글리코시다아제 저해제로서 피라노[3,2-d][1,3]티아졸 | |
| JP7082446B2 (ja) | スルホキシイミングリコシダーゼ阻害剤 | |
| US11795165B2 (en) | Tetrahydro-benzoazepine glycosidase inhibitors | |
| CA2899088C (en) | Thiazole and oxazole compounds as glycosidase inhibitors | |
| CA3053200C (en) | Sulfoximine glycosidase inhibitors | |
| US12016852B2 (en) | Pyrrolidine glycosidase inhibitors | |
| AU2019200339A1 (en) | Glycosidase inhibitors | |
| TWI691486B (zh) | 環狀胺衍生物及其醫藥用途 | |
| AU2017400271A1 (en) | Sulfoximine glycosidase inhibitors | |
| EP3585783A2 (en) | Sulfoximine glycosidase inhibitors | |
| HK1196607B (en) | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors | |
| EA037845B1 (ru) | Производные 4-гидрокси-2-фенил-1,3-тиазол-5-ил метанона как антагонисты trpm8 | |
| CN113735825A (zh) | 1,2,3,6-四氢吡啶类化合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |